Abstracts tagged "Disease Activity"

Abstract Number: 16 • 2016 ACR/ARHP Annual Meeting
Differences Between Patient and Physician Global Assessment on Rheumatoid Arthritis Disease Activity Status in High and Lower Income Countries Contribute to Inequity
SA Bergstra¹, R van den Berg¹, A Chopra², JAP da Silva³, D Vega-Morales⁴, N Govind⁵, TWJ Huizinga⁶ and RBM Landewé^7,8, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, SRHUC, Coimbra, Portugal, Coimbra, Portugal, ⁴Universidad Autónoma de Nuevo Léon, Monterrey, Mexico, Monterrey, Mexico, ⁵Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁶Leiden University Medical Centre, Leiden, Netherlands, ⁷Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁸Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients score their global disease activity (ptGD) on average higher than physicians (phGD). This difference can vary between countries with high…
Abstract Number: 510 • 2016 ACR/ARHP Annual Meeting
C-Reactive Protein and Disease Activity in Rheumatoid Arthritis: Impact of Obesity and Adiposity
Michael D. George¹, Jon T. Giles², Patricia P. Katz³, Said Ibrahim⁴, Grant W. Cannon⁵, Bryant R. England⁶, Liron Caplan⁷, Brian Sauer⁸, Kaleb Michaud⁹, Ted R Mikuls¹⁰ and Joshua F. Baker¹, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, ⁶Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ⁸IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: C-reactive protein (CRP) is used to assess disease activity in rheumatoid arthritis (RA), and previous work suggests that adiposity also impacts CRP levels. This…
Abstract Number: 722 • 2016 ACR/ARHP Annual Meeting
Impact of Aerobic Fitness on Axial Spondyloarthritis Activity: Systematic Review and Meta-Analysis of Controlled Studies
Frank Verhoeven¹, Xavier Guillot², Clément Prati³, Nicolas Tordi⁴, Céline Demougeot¹ and Daniel Wendling⁵, ¹EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ²EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, ³FDE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE,, Bourgogne Franche-Comté University, Besançon, France, ⁵Service de Rhumatologie, CHU Jean Minjoz, Besancon, France
Background/Purpose: The current ASAS recommendations for the management of the ankylosing spondylitis suggest, beside pharmacological therapy, a significant part of physical therapy with supervised exercises.…
Abstract Number: 1158 • 2016 ACR/ARHP Annual Meeting
Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with Rheumatoid Arthritis
SeungIn Paek¹, Seo Hwa Kim², Haneul Kim³, Min Kyung Chung⁴, Jennifer Lee⁵, Seung-Ki Kwok⁶, Ji Hyeon Ju⁷, Sung-Hwan Park⁷ and Kyeong Yae Sohng⁸, ¹Center for Rheumatic Diseases, Seoul ST Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology,, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁸College of Nursing, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: The purpose of this study was to investigate the effects of an educational program using T2T (Treat RA to Target, T2T) strategy on Korean…
Abstract Number: 1470 • 2016 ACR/ARHP Annual Meeting
Moderate to Severe Disease Activity in Rheumatoid Arthritis Is Associated with Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake
Isabelle Amigues¹, Jon T. Giles², Afshin Zartoshti³, Rachelle Morgenstern⁴, Raul Flores⁵, Sabahat Bokhari⁶ and Joan Bathon⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁴Cardiology, columbia university college of physicians and surgeons, New York city, NY, ⁵Medicine, Columbia University, New York Presbyterian, New York city, NY, ⁶Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: RA patients are at increased risk for developing heart failure (HF) even after controlling for coronary artery disease (CAD), indicating that factors other than…
Abstract Number: 1700 • 2016 ACR/ARHP Annual Meeting
Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease…
Abstract Number: 2082 • 2016 ACR/ARHP Annual Meeting
Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Jianlin Huang¹, Hongzhi Wang², Jing Yang³, Wenqiang Fan⁴, Hua Wei⁵, Rong Mu⁶, Xinwang Duan⁷, Xiangyuan Liu⁸, Fang He⁹, Zhenchun Zhang¹⁰, Fei Xiao¹¹, Hui Xiao¹¹, Yuhua Jia¹¹, Yuan Liu¹¹, Li Zhang¹¹, Bing Wu¹¹ and Xiaofeng Li¹², ¹Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁸Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ⁹Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁰People's Hospital of Linyi, Shandong, Linyi, China, ¹¹Gothic Internet Technology Corporation, Shanghai, China, ¹²The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-target (T2T) is a widely accepted cretria as…
Abstract Number: 2518 • 2016 ACR/ARHP Annual Meeting
Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
Nicola J Gullick¹, Fowzia Ibrahim², Aneela Mian¹, Alexandra Vincent³, Gabriel Panayi¹, Brian Tom⁴, David L. Scott¹ and Bruce Kirkham³, ¹Rheumatology, King's College London, London, United Kingdom, ²Academic Rheumatology Dept, King's College London, London, United Kingdom, ³Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
Background/Purpose: There has been increasing emphasis on intensive treatment of RA but little direct evidence of the impact of such strategies on long term outcome.…
Abstract Number: 2780 • 2016 ACR/ARHP Annual Meeting
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…
Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting
Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Susan J. Bartlett^1,2, Orit Schieir³, Kathleen Andersen⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet E. Pope⁹, J Carter Thorne¹⁰, Diane Tin¹¹, Vivian P. Bykerk¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁶1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting
Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4
James Gwinnutt¹, Deborah P.M. Symmons^1,2, Alex J Macgregor^3,4, Jacqueline Chipping^3,4, Tarnya Marshall^3,4, Mark Lunt¹ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁴School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom
Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
Abstract Number: 511 • 2016 ACR/ARHP Annual Meeting
Complement C3 and C4 Levels and Its Correlation with Disease Activity in Rheumatoid Arthritis Patients
Julia Sosa¹, Silvia Beatriz Papasidero², María Alejandra Medina¹, Diana Klajn³, Rafael Chaparro del Moral², José Angel Caracciolo⁴, Luciana Casalla⁵, Lucía Zárate⁵, Nieves Capozzi⁵, Josefina Marcos⁶, Mercedes Argentina García⁶, Ana Quinteros⁷, Maria Olga Leal⁷, Dora Lia Vásquez⁷, María Inés Stancich⁸, Analia Alvarez⁹, Carolina Sanchez Andía⁹, Karin Kirmayr¹⁰, María de los Ángeles Correa¹¹ and A. Constantino¹², ¹Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Rheumatology Department, Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Research Committee, Research Committee, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁴Rhematology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁵Rheumatology Section, Hospital Posadas, Buenos Aires, Argentina, ⁶Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ⁷Centro Integral De Reumatologia, Tucumán, Argentina, ⁸Rheumatology Department, Hospital Nacional De Clínicas, Córdoba, Argentina, ⁹Rheumatology Department, Hospital Penna, Buenos Aires, Argentina, ¹⁰Rheumatology Department, Sanatorio San Carlos, Buenos Aires, Argentina, ¹¹Rheumatology Department, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹²Hospital Nacional De Clínicas, Córdoba, Argentina
COMPLEMENT C3 AND C4 LEVELS AND ITS CORRELATION WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS Background/Purpose: Cytokines play a major role in the pathogenesis…
Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting
Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform
Chaim Putterman¹, Pennina Safer², Keren Jakobi², Rachel Sorek², Ilana Gilkaite², Kyle Ferber³, Steve Wallace³, Amanda Harris Altice³, D. Scott Batty³ and Irun R Cohen^2,4, ¹Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray LTD, Rehovot, Israel, ³ImmunArray Inc., Richmond, VA, ⁴Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
Abstract Number: 1471 • 2016 ACR/ARHP Annual Meeting
Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment
Isabelle Amigues¹, Jon T. Giles², Afshin Zartoshti³, Rachelle Morgenstern⁴, Raul Flores⁵, Sabahat Bokhari⁶ and Joan Bathon⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁴Cardiology, columbia university college of physicians and surgeons, New York city, NY, ⁵Medicine, Columbia University, New York Presbyterian, New York city, NY, ⁶Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Symptomatic heart failure (HF) and HF-associated mortality rates are higher in RA compared with the non-RA population, even after controlling for coronary artery…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].